Table 3 Adverse events in patients who completed the two-day course of artemisinin-piperaquine (ARPQ, n = 62) and the three-day course of artesunate-amodiaquine (ASAQ, n = 63) in Vietnamese patients with Plasmodium falciparum malaria

ARPQ

Before treatment

24 h after 1 ^st dose

24 h after 2 ^nd dose

48 h after 2 ^nd dose

Fever

88.7% (55/62)

29.0% (18/62)

1.6% (1/62)

NR

Headache

87.1% (54/62)

48.4% (30/62)

1.6% (1/62)

1.6% (1/62)

Nausea

29.0% (18/62)

3.2% (2/62)

NR

NR

Stomach pain

1.6% (1/62)

NR

NR

NR

Vomiting

1.6% (1/62)

NR

NR

NR

Dizziness

27.4% (17/62)

3.2% (2/62)

NR

NR

Tiredness

61.3% (38/62)

25.8% (16/62)

3.2% (2/62)

1.6% (1/62)

Anorexia

43.5% (27/62)

9.7% (6/62)

1.6% (1/62)

1.6% (1/62)

ASAQ

Before treatment

24 h after1 ^st dose

24 h after 2 ^nd dose

24 h after 3 ^rd dose

Fever

82.5% (52/63)

20.6% (13/63)

3.2% (2/63)

NR

Headache

95.2% (60/63)

46.0% (29/63)

3.2% (2/63)

NR

Nausea

41.3% (26/63)

19.0% (12/63)

1.6% (1/63)

NR

Stomach pain

NR

NR

NR

NR

Vomiting

3.2% (2/63)

3.2% (2/63)

NR

NR

Dizziness

25.4% (16/63)

3.2% (2/63)

NR

NR

Tiredness

69.8% (44/63)

30.2% (19/63)

3.2% (2/63)

NR

Anorexia

46.0% (29/63)

20.6% (13/63)

NR

NR